What is Spec Perindopril?
Spec Perindopril is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood pressure can reduce the risk of strokes and heart attacks.
Spec Perindopril works by blocking a substance in the body that causes the blood vessels to tighten. As a result, Spec Perindopril relaxes the blood vessels. This lowers blood pressure and increases the supply of blood and oxygen to the heart.
Spec Perindopril is also used in patients with coronary artery disease to prevent heart attacks.
Spec Perindopril is available only with your doctor's prescription.
Spec Perindopril indications
Stable Coronary Artery Disease: Reduce the risk of cardiovascular mortality or nonfatal myocardial infarction.
Conventional treatment for management of coronary artery disease eg, antiplatelet, antihypertensive or lipid-lowering therapy.
Hypertension: Treatment of patients with essential hypertension. It may be used alone or given with other classes of antihypertensives, especially thiazide diuretics.
When using Spec Perindopril, consideration should be given to the fact that another ACE inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether Spec Perindopril has a similar potential.
In considering use of Spec Perindopril, it should be noted that in controlled trials, ACE inhibitors have an effect on blood pressure that is less in Black patients than in non-Blacks. In addition, it should be noted that Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-Blacks.
How should I use Spec Perindopril?
Use Spec Perindopril as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Spec Perindopril by mouth with or without food.
- Take Spec Perindopril on a regular schedule to get the most benefit from it.
- Taking Spec Perindopril at the same time(s) each day will help you to remember to take it.
- Continue taking Spec Perindopril even if you feel well. Do not miss any doses.
- If you miss a dose of Spec Perindopril, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Spec Perindopril.
Uses of Spec Perindopril in details
Spec Perindopril is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication is also used to prevent heart attacks in patients with a certain type of heart disease (stable coronary artery disease).
Spec Perindopril belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily.
OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.
This medication may also be used to treat congestive heart failure and to help protect the kidneys from damage due to diabetes.
How to use Spec Perindopril
Take this medication by mouth as directed by your doctor, usually once or twice daily. The dosage is based on your medical condition and response to treatment.
To reduce your risk of side effects, your doctor may direct you to start this medication at a low dose and gradually increase your dose. Follow your doctor's instructions carefully.
Take this medication regularly to get the most benefit from it. To help you remember, take it at the same time(s) each day. It is important to continue taking this medication even if you feel well. Most people with high blood pressure do not feel sick.
It may take several weeks before you get the full benefit of this drug.
Tell your doctor if your condition does not get better or if it gets worse (for example, your blood pressure readings remain high or increase).
Spec Perindopril description
Spec Perindopril is the tert-butylamine salt of Spec Perindopril, the ethyl ester of a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Spec Perindopril tert-butylamine is chemically described as (2S, 3αS, 7αS)-1-[(S)-N-[(S)-1-Carboxy-butyl] alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester, compound with tert-butylamine (1:1). Its molecular formula is C19H32N2O5C4H11N.
Spec Perindopril tert-butylamine has molecular weight of 368.47 (free acid) or 441.61 (salt form).
Spec Perindopril is the free acid form of tert-butylamine, is a pro-drug and metabolized in vivo by hydrolysis of the ester group to form perindoprilat, the biologically active metabolite.
Spec Perindopril dosage
Spec Perindopril Dosage
Generic name: Spec Perindopril erbumine 2mg
Dosage form: tablet
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Hypertension
Use in Uncomplicated Hypertensive Patients: In patients with essential hypertension, the recommended initial dose is 4 mg once a day. The dose may be titrated, as needed to a maximum of 16 mg per day. The usual maintenance dose range is 4 mg to 8 mg administered as a single daily dose or in two divided doses.
Use in Elderly Patients: The recommended initial daily dosage of Spec Perindopril for the elderly is 4 mg daily, given in one or two divided doses. Experience with Spec Perindopril is limited in the elderly at doses exceeding 8 mg. Dosages above 8 mg should be administered with careful blood pressure monitoring and dose titration.
Use with Diuretics: In patients who are currently being treated with a diuretic, symptomatic hypotension can occur following the initial dose of Spec Perindopril. Consider reducing the dose of diuretic prior to starting Spec Perindopril.
Stable Coronary Artery Disease
In patients with stable coronary artery disease, Spec Perindopril should be given at an initial dose of 4 mg once daily for 2 weeks, and then increased as tolerated, to a maintenance dose of 8 mg once daily. In elderly patients (greater than 70 years), Spec Perindopril should be given as a 2 mg dose once daily in the first week, followed by 4 mg once daily in the second week and 8 mg once daily for maintenance dose if tolerated.
Dose Adjustment in Renal Impairment and Dialysis
Perindoprilat elimination is decreased in renally impaired patients. Spec Perindopril is not recommended in patients with creatinine clearance <30 mL/min. For patients with lesser degrees of impairment, the initial dosage should be 2 mg/day and dosage should not exceed 8 mg/day. During dialysis, Spec Perindopril is removed with the same clearance as in patients with normal renal function.
More about Spec Perindopril (Spec Perindopril)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- En Espanol
- 0 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Spec Perindopril
- Spec Perindopril (Advanced Reading)
Professional resources
- Spec Perindopril (AHFS Monograph)
- Spec Perindopril (FDA)
Related treatment guides
- Coronary Artery Disease
- Diabetic Kidney Disease
- Heart Attack
- Heart Failure
- High Blood Pressure
- More (1) »
Spec Perindopril interactions
See also:
What other drugs will affect Spec Perindopril?
Diuretics: Patients on diuretics and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of Spec Perindopril therapy. The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Spec Perindopril. If diuretics cannot be interrupted, close medical supervision should be provided with the 1st dose of Spec Perindopril, for at least 2 hrs and until blood pressure has stabilized for another hour.
The rate and extent of Spec Perindopril absorption and elimination are not affected by concomitant diuretics. The bioavailability of perindoprilat was reduced by diuretics, however, and this was associated with a decrease in plasma ACE inhibition.
Potassium Supplements and Potassium-Sparing Diuretics: Spec Perindopril may increase serum potassium because of its potential to decrease aldosterone production. Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patient's serum potassium should be monitored frequently.
Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. These drugs should be co-administered with caution and frequent monitoring of serum lithium concentration is recommended. Use of a diuretic may further increase the risk of lithium toxicity.
Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including Spec Perindopril.
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when co-administered with Spec Perindopril, but an effect of digoxin on the plasma concentration of Spec Perindopril/perindoprilat has not been excluded.
Gentamicin: Animal data have suggested the possibility of interaction between Spec Perindopril and gentamicin. However, this has not been investigated in human studies. Co-administration of both drugs should proceed with caution.
Food Interaction:
Oral administration of Spec Perindopril with food does not significantly lower the rate or extent of Spec Perindopril absorption relative to the fasted state. However, the extent of biotransformation of Spec Perindopril to the active metabolite, perindoprilat, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. In clinical trials, Spec Perindopril was generally administered in a nonfastingstate.
Spec Perindopril side effects
See also:
What are the possible side effects of Spec Perindopril?
Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Clinical Trials Experience
The following adverse reactions are discussed elsewhere in labeling:
- Anaphylactoid reactions, including angioedema
- Hypotension
- Neutropenia and agranulocytosis
- Impaired renal function
- Hyperkalemia
- Cough
Hypertension
Spec Perindopril has been evaluated for safety in approximately 3,400 patients with hypertension in U.S. and foreign clinical trials. The data presented here are based on results from the 1,417 Spec Perindopril-treated patients who participated in the U.S. clinical trials. Over 220 of these patients were treated with Spec Perindopril® (Spec Perindopril erbumine) for at least one year.
In placebo-controlled U.S. clinical trials, the incidence of premature discontinuation of therapy due to adverse events was 6.5% in patients treated with Spec Perindopril and 6.7% in patients treated with placebo. The most common causes were cough, headache, asthenia and dizziness.
Among 1,012 patients in placebo-controlled U.S. trials, the overall frequency of reported adverse events was similar in patients treated with Spec Perindopril and in those treated with placebo (approximately 75% in each group). The only adverse events whose incidence on Spec Perindopril was at least 2% greater than on placebo were cough (12% vs. 4.5%) and back pain (5.8% vs. 3.1%).
Dizziness was not reported more frequently in the Spec Perindopril group (8.2%) than in the placebo group (8.5%), but its likelihood increased with dose, suggesting a causal relationship with Spec Perindopril.
Stable Coronary Artery Disease
Spec Perindopril has been evaluated for safety in EUROPA, a double-blind, placebo-controlled study in 12,218 patients with stable coronary artery disease. The overall rate of discontinuation was about 22% on drug and placebo. The most common medical reasons for discontinuation that were more frequent on Spec Perindopril than placebo were cough, drug intolerance and hypotension.
Postmarketing Experience
Voluntary reports of adverse events in patients taking Spec Perindopril that have been received since market introduction and are of unknown causal relationship to Spec Perindopril include: cardiac arrest, eosinophilic pneumonitis, neutropenia/agranulocytosis, pancytopenia, anemia (including hemolytic and aplastic), thrombocytopenia, acute renal failure, nephritis, hepatic failure, jaundice (hepatocellular or cholestatic), symptomatic hyponatremia, bullous pemphigoid, pemphigus, acute pancreatitis, falls, psoriasis, exfoliative dermatitis and a syndrome which may include: arthralgia/arthritis, vasculitis, serositis, myalgia, fever, rash or other dermatologic manifestations, a positive antinuclear antibody (ANA), leukocytosis, eosinophilia or an elevated erythrocyte sedimentation rate (ESR).
Clinical Laboratory Test Findings
Hematology
Small decreases in hemoglobin and hematocrit occur frequently in hypertensive patients treated with Spec Perindopril, but are rarely of clinical importance. In controlled clinical trials, no patient was discontinued from therapy due to the development of anemia. Leukopenia (including neutropenia) was observed in 0.1% of patients in U.S. clinical trials.
Liver Function Tests
Elevations in ALT (1.6% Spec Perindopril versus 0.9% placebo) and AST (0.5% Spec Perindopril versus 0.4% placebo) have been observed in placebo-controlled clinical trials. The elevations were generally mild and transient and resolved after discontinuation of therapy.
Spec Perindopril contraindications
See also:
What is the most important information I should know about Spec Perindopril?
Hypersensitivity to Spec Perindopril or to any of the excipients of Spec Perindopril or to any other ACE inhibitor; history of angioedema associated with previous ACE inhibitor therapy; hereditary or idiopathic angioedema.
Due to the presence of lactose, patients with rare hereditary problems of galactose intolerance, glucose-galactose malabsorption, or the Lapp lactase deficiency should not take Spec Perindopril.
Use in pregnancy: Spec Perindopril should not be used during the 1st trimester of pregnancy. When a pregnancy is planned or confirmed, the switch to an alternative treatment should be initiated as soon as possible. Controlled studies with ACE inhibitors have not been done in humans, but in a limited number of cases with 1st trimester exposure, there do not appear to have been any malformations consistent with human foetotoxicity as described as follows.
Spec Perindopril is contraindicated during the 2nd and 3rd trimesters of pregnancy.
Prolonged ACE inhibitor exposure during the 2nd and 3rd trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia).
Should exposure to Spec Perindopril have occurred from the 2nd trimester of pregnancy, ultrasound check of renal function and skull is recommended.
Active ingredient matches for Spec Perindopril:
Perindopril in South Africa.
List of Spec Perindopril substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Prestoril | |
| Tablet; Oral; Perindopril Erbumine 4 mg | |
| Prestpril (Romania) | |
| Prexanil (Croatia (Hrvatska), Czech Republic, Estonia, Serbia, Slovenia) | |
| Prexanil A (Croatia (Hrvatska)) | |
| Prexanil Combi A (Croatia (Hrvatska)) | |
| Prexum (Indonesia, South Africa) | |
| Pricoron (Czech Republic, Romania) | |
| Prilam (Georgia) | |
| Prindace (Ireland) | |
| Prindex (Bulgaria, Estonia, Latvia, Lithuania, Romania) | |
| Syrup; Oral; Carbinoxamine Maleate 25 mg; Pseudoephedrine Hydrochloride 60 mg / 5 ml (Medicamenta) | |
| Tablet, Film-Coated; Oral; Carbinoxamine Maleate 2.5 mg; Pseudoephedrine Hydrochloride 60 mg (Medicamenta) | |
| Prinopril (Bulgaria) | |
| Pritnox (Poland) | |
| Procaptan (Italy) | |
| Provinace (Malaysia) | |
| Provinace 4 mg x 3 Blister x 10 Tablet | |
| Provinace 4 mg x 30's | |
| Ran-Perindopril (South Africa) | |
| Ranbapril (Serbia) | |
| Relika (Croatia (Hrvatska)) | |
| Revosyl 8 | |
| Rindolex (Slovenia) | |
| Serperil (Turkey) | |
| Spopress (Poland) | |
| Stoppress (Romania) | |
| Stopress (Bulgaria, Estonia, Latvia, Lithuania) | |
| Terc-butilaminijev (Slovenia) | |
| Terry White Chemists Perindopril (Australia) | |
| Tablet; Oral; Perindopril Erbumine 2 mg | |
| Tablet; Oral; Perindopril Erbumine 4 mg | |
| Tablet; Oral; Perindopril Erbumine 8 mg | |
| Terry White Chemists Perindopril Arginine (Australia) | |
| Trezen (Romania) | |
| Vectoryl (South Africa) | |
| Versil (Bangladesh) | |
| Versil 6 mg Tablet (Silver Biotech (Sanify Healthcare Pvt. Ltd.)) | $ 0.18 |
| Vidotin (Czech Republic, Estonia, Latvia, Lithuania, Poland, Romania) | |
| Vidotin 4 mg (Hungary) | |
| Vidotin 8 mg (Hungary) | |
| Viritin (Vietnam) | |
| Viritin 4 (Vietnam) | |
| Viritin 4 4 mg x 1 Blister x 30 Tablet | |
| Zimpril | |
| Zimpril 4mg Tablet (Zee Laboratories) | $ 0.10 |
| Zimpril 8mg Tablet (Zee Laboratories) | $ 0.17 |
| Zydus Perindopril (South Africa) | |
See 519 substitutes for Spec Perindopril | |
References
- PubChem. "PERINDOPRIL". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "PERINDOPRIL". http://www.drugbank.ca/drugs/DB00790 (accessed September 17, 2018).
- MeSH. "Antihypertensive Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Spec Perindopril are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Spec Perindopril. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
